SAAKSHI

Saakshi Medtech and Panels Limited

Listed company · ISIN INE0PSK01027 · NSE ST · FV ₹10
Last price
₹365
0.00%today
What this company does

Saakshi Medtech and Panels Limited is a listed company. It booked ₹57 cr of revenue in its latest half year (H2 FY26) and kept 9.9% of sales as profit.

55out of 100
Equitytale Health Score
Mixed

Healthier than 55% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,334–2,885 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
62

At close. Not part of the score.

Profitability & returns54

How much profit it earns on the money it employs

Balance sheet57

How much it owes, and whether earnings cover the interest

Cash quality67

Whether reported profit actually arrives as cash

Valuation16

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Sales up 19% vs last year
✓ Profit up 349% vs last year
✓ Promoters hold 75%
✓ No promoter shares pledged
Watch-outs
None flagged from our data

What if I invest in SAAKSHI?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹365▲ 0.00%
latest close · 2026-10-01
52-wk low ₹26552 sessions so far52-wk high ₹381
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio56.9High
LowAverageHigh
P/B ratio6.95High
Below bookModerateHigh
EV / EBITDA37.5High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity12.2%Fair
WeakFairStrong ▸15%
Return on capital14.0%Fair
WeakFairStrong
Net margin9.9%Decent
ThinDecentStrong
EBITDA margin15.6%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.27Comfortable
LowModerateHigh ▸1
Interest cover8.2×Strong
RiskyOkayStrong ▸5×
Current ratio2.06Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹644 cr
Book value
₹52
EPS
₹3.21
latest half year
Net debt
₹24 cr
owes more than its cash
Enterprise value
₹668 cr
EBITDA
₹18 cr
annualised
EBIT
₹18 cr
annualised
Operating margin
15.6%
Return on assets
7.2%
Earnings yield
1.76%
P/S
5.63
Sales / share
₹64.8
Tax rate
27.7%
Face value
₹10
Shares
1.8 cr
Working capital
₹32 cr
Current assets
₹61 cr
Current liabilities
₹30 cr
Delivery %
90.6%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹19–₹57, midpoint ₹29

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹57 cr
Other Income₹22.3 L
Total Income₹57 cr
Cost of Materials₹35 cr
Purchases of Stock-in-Trade₹94.5 L
Inventory Change (±)₹-5 cr
Employee Benefit Expense₹9 cr
Finance Costs₹1 cr
Other Expenses₹5 cr
Total Expenses₹50 cr
Profit before Tax₹8 cr
Tax Expense₹2 cr
Net Profit₹6 cr
Net margin on total income9.9%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹31 cr54.8%
Employee benefit expense₹9 cr16.4%
Finance costs₹1 cr1.9%
Other expenses₹8 cr13.2%
Tax expense₹2 cr3.8%
Profit for the period₹6 cr9.9%
Total income ₹57 cradds up to ₹100 ✓
Half-yearly results · consolidated (₹ cr)
MetricH2 FY25H1 FY26H2 FY26
Revenue48 cr58 cr57 cr
Total income48 cr59 cr57 cr
Expenses46 cr50 cr50 cr
Profit before tax2 cr9 cr8 cr
Tax54.8 L2 cr2 cr
Net profit (owners' share)1 cr7 cr6 cr
Net margin (owners' share, on revenue)2.6%11.4%9.9%
EPS (₹)0.713.763.21
YoY (latest quarter): total income +18.9% · net profit +349.5%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹157 cr
Shareholder equity
₹93 cr
parent shareholders
Total debt
₹25 cr
Cash
₹2 cr
Who owns it · 2026-08-24
No pledge
Promoter
74.8%
FII / Foreign
0.1%
DII / Domestic
0.3%
Retail / others
24.8%
Promoter stake up 1.2% over the last 5 quarters.
Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 3 named members
owning 74.8% between them · as of 2026-08-24
CHITRA VIJAY LATKAR66.27%
MAYURI ANIKET LATKAR4.71%
ANIKET VIJAY LATKAR3.84%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.